drugset / Trial / NCT06400719

Pilot Study of AVT16 in Healthy Adult Subjects

NCT06400719

Phase 1 Completed 18 enrolled Alvotech Swiss AG
NaSingle-groupOpen-labelTreatment

Summary

This is a pilot study in healthy adult subjects to evaluate the safety and tolerability of AVT16 after administration of a single intravenous administration. Pharmacokinetics and immunogenicity of AVT16 will also be evaluated.

Timeline

Start
2024-05-29
Primary completion
2024-11-06
Completion
2024-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AVT16 Unknown 300 mg Intravenous

Indications

No indication recorded.